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Abstract
Extensive experimental information supports the formation of ligand-specific conformations of G protein-coupled receptors
(GPCRs) as a possible molecular basis for their functional selectivity for signaling pathways. Taking advantage of the recently
published inactive and active crystal structures of GPCRs, we have implemented an all-atom computational strategy that
combines different adaptive biasing techniques to identify ligand-specific conformations along pre-determined activation
pathways. Using the prototypic GPCR b2-adrenergic receptor as a suitable test case for validation, we show that ligands
with different efficacies (either inverse agonists, neutral antagonists, or agonists) modulate the free-energy landscape of the
receptor by shifting the conformational equilibrium towards active or inactive conformations depending on their elicited
physiological response. Notably, we provide for the first time a quantitative description of the thermodynamics of the
receptor in an explicit atomistic environment, which accounts for the receptor basal activity and the stabilization of different
active-like states by differently potent agonists. Structural inspection of these metastable states reveals unique
conformations of the receptor that may have been difficult to retrieve experimentally.
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Introduction
G-protein coupled receptors (GPCRs) are versatile signaling
proteins that functionally couple a host of extracellular stimuli to
intracellular effectors, thus mediating several vital cellular
responses. The majority of marketed drugs act as agonists, inverse
agonists, or antagonists at these receptors depending on whether
they increase, reduce, or have no effect on the so-called ‘basal
activity’ that characterizes unliganded GPCRs for diffusible
ligands. Not only can a specific GPCR activate different G-
protein or arrestin isoforms [1], but a single ligand can display
different efficacy for different signaling pathways, an observation
that has been dubbed ‘‘functional selectivity’’, ‘‘agonist traffick-
ing’’, ‘‘biased agonism’’, ‘‘differential engagement’’, or ‘‘protean
agonism’’ in the literature [2–6].
At the molecular level, a simple explanation for this phenom-
enon is that ligands with varied efficacies can shift the
conformational equilibrium of a GPCR towards different
conformations of the receptor, which in turn can activate one or
another intracellular protein. Although several spectroscopy
studies (e.g., for the b2-adrenergic receptor, herein referred to as
B2AR, see [7–9]) have been instrumental in showing that ligands
with different efficacies stabilize GPCR conformational states that
are structurally and kinetically distinguishable, perhaps the most
direct evidence of ligand-induced conformational specificity comes
from the recent high-resolution crystallographic structures of
several different ligand-bound GPCRs. In the majority of cases,
these structures were obtained in the presence of an inverse
agonist, and therefore in an inactive state. Only very recently have
high-resolution crystal structures of agonist-bound GPCRs started
to appear in the literature [10–15]. However, possibly restrained
by crystallization conditions, not all these agonist-bound structures
present the features that are usually attributed to an active GPCR
conformation, most typically: the large outward movement of
transmembrane helix 6 (TM6) with respect to the center of the
receptor helical bundle, which is accompanied by the disruption of
an important salt bridge between the conserved D/E3.49-R3.50
pair and E6.30, commonly referred to as the ‘‘ionic lock’’. Residue
numbering here and throughout the text follows the Ballesteros-
Weinstein notation [16]. According to this notation, each residue
is indicated by a two-number identifier N1.N2 where N1 is the
number of the transmembrane helix, and N2 is the residue
number on that helix relative to its most conserved position, which
is designated N2=50. We direct the reader elsewhere (e.g.,
[17,18]) for recent reviews of all the relevant structural changes
that have been attributed by various biophysical techniques to
active forms of GPCRs.
A different extent of structural rearrangement was noted at the
binding site of high-resolution crystal structures of GPCRs
depending on the type of ligand to which they were bound. For
instance, only minor local structural changes were noted between
the high-resolution crystal structures of the B2AR in the presence
of inverse agonists such as carazolol [19], timolol [20], ICI-
118,551 [21], or a compound deriving from virtual screening [21]
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pronounced differences were noted by comparing these inverse
agonist/antagonist-bound binding pockets with those stabilized by
full agonists (i.e., either the covalently-bound ligand FAUC50 [11]
or BI-167107 [10]). Among them, the most notable differences
were the hydrogen bonding contacts that only agonists formed
with S5.42 and S5.46 on TM5. Similar interactions helped
discriminate between inverse agonist-bound crystal structures of
the b1-adrenergic receptor (B1AR) and structures obtained in the
presence of full agonists (e.g., isoprenaline or carmoterol) [13].
Notably, only one of these two hydrogen bonds involving TM5,
specifically the interaction with S5.42, was also present in
structures stabilized by the partial agonists salbutamol or
dobutamine, suggesting a distinguishable binding mode between
full and partial agonist structures [13]. Analogous to the cases of
the B1AR and B2AR, where specific residues (i.e., S5.46) are
found to bind uniquely to agonists, key residues (S7.42 and H7.43)
that bind agonists (either adenosine or NECA) but not antagonists
(ZM241385) were revealed by the very recent crystal structures of
a thermostabilized construct of the adenosine A2A receptor [15].
Unlike another recent crystal structure of this receptor stabilized
by both T4-lysozyme and the conformationally selective agonist
UK-432097 [12], these agonist-bound structures did not display
changes at the cytoplasmic side that resemble those of an active
state of a GPCR. In addition to the crystal structure of the
adenosine A2A receptor bound to UK-432097 [12], these more
marked changes at the cytoplasmic side have so far only been
observed in the high-resolution crystal structures of opsin [22,23],
Meta II rhodopsin [14], and the nanobody-stabilized B2AR [10].
Despite these recent remarkable achievements in structural
biology of GPCRs, the majority of pharmacologically relevant
ligands of these receptors do not appear to be ideally suited for the
stabilization and crystallization of these receptors, most likely
because of their low affinity, slow off-rate, and poor solubility. Not
only might this prevent the identification of physiologically
relevant conformational states of a given GPCR, but it is
considered a limiting bottleneck for the characterization of
different structures of these receptors. Molecular dynamics (MD)
simulations can help to fill this information gap by enabling an
atomic-level characterization of ligand-specific conformations that
are impossible or difficult to retrieve experimentally. Moreover,
these simulations allow extension of static structural data into
dynamic representations, thus laying the basis for a mechanistic
understanding of the selective activation of GPCR-mediated
signaling pathways.
To enable characterization of large conformational changes
within the limited timescales commonly accessible to MD
simulations, and to evaluate the extent to which ligands with
different efficacies affect the free-energy landscape of GPCRs, we
implemented a computational strategy employing a combination
of different adaptive biasing techniques. Specifically, we used well-
tempered metadynamics [24] to identify metastable states of a
GPCR along putative activation pathways between inactive and
active crystallographic states determined by adiabatic biased MD.
We tested the accuracy of this strategy in reproducing crystallo-
graphic [19,21] and/or spectroscopic [7–9] data available for the
B2AR in its interaction with either a full agonist (i.e., epinephrine),
a weak partial agonist (i.e., dopamine), a very weak partial agonist
(i.e., catechol), two inverse agonists (i.e. ICI-118,551 and
carazolol), or one neutral antagonist (i.e., alprenolol). The results
show a clear ligand-induced modulation of the free-energy
landscape of the receptor with shifts in the conformational
equilibrium towards inactive or active conformations depending
on the physiological response elicited by the simulated ligand.
Materials and Methods
System and Simulation Setup
A model of the B2AR (Figure S1) was prepared starting from
one of the available crystal structures of this receptor (PDB ID:
2RH1), removing the lysozyme insertion, and modeling the
missing intracellular loop 3 (IL3) with the Rosetta ab-initio loop
modeling protocol [25]. The intracellular loop 2 (IL2), which is
probably misfolded [26,27] in the inactive structure of the B2AR
(2RH1), but in a helical conformation in the active nanobody-
stabilized crystal (3P0G) of the receptor, was also replaced by the
lowest-energy Rosetta model with a helical fold. The resulting
receptor model was embedded into an explicit 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC)/10% cholesterol
membrane bilayer using a pre-equilibrated 868610 nm patch
hydrated with SPC/E water molecules, and the procedure
described in [28]. As found in the crystal structure [19], one
palmitoyl group was covalently attached to a C-terminal residue
(Cys 341) of the receptor before insertion in the membrane. The
system was then hydrated with SPC/E water molecules [29] and
Na
+ and Cl
– ions were added to ensure charge neutrality.
The resulting system of ,50,000 total atoms was equilibrated
with unbiased MD simulations for 20 nanoseconds (ns) using the
Optimized Potentials for Liquid Simulations all-atom (OPLS-AA)
force field [30] for the receptor and united-atoms Berger
parameters for the lipids [31]. The Gromacs 4.0.7 [32] package
enhanced with the Plumed plug-in [33] was used for all
simulations. Specifically, NPT simulations were carried out under
periodic boundary conditions, using the Parrinello-Rahman
algorithm [34] with a time constant of 1.0 ps and a reference
pressure of 1 bar to control pressure, and the Nose-Hoover [35]
algorithm with a time constant of 1.0 ps to maintain a constant
temperature of 300 K. Prior to production runs (summarized in
Table S1), the system was equilibrated by a series of three 0.2 ns
runs with progressively weaker restraints on the protein backbone
followed by a 3.0 ns unconstrained equilibration. We used the
standard Gromacs leap-frog [32] algorithm with a time step of
2.0 fs, LINCS algorithm [36] to preserve the bond lengths, and
SETTLE algorithm [37] to maintain the geometry of the water
Author Summary
G protein-coupled receptors (GPCRs) constitute one of the
most important classes of cellular targets owing to their
known response to a host of extracellular stimuli, and
consequent involvement in numerous vital biological
processes. Compelling evidence herein referred to as
‘functional selectivity’ shows that ligands with varied
efficacies can stabilize different GPCR conformations that
may selectively interact with different intracellular pro-
teins, and therefore induce different biological responses.
Understanding how this selectivity is achieved may lead to
the discovery of drugs with improved therapeutic proper-
ties. We propose here a computational strategy that
enables identification of the specific conformations
assumed by a GPCR when interacting with ligands that
elicit different physiological responses. Not only can these
computational models help bridge the information gap in
structural biology of GPCRs, but they can be used for
virtual screening, and possibly lead to the structure-based
rational discovery of novel ‘biased’ ligands that are capable
of selectively activating one cellular signaling pathway
over another.
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range cutoff of 0.9:1.4 nm and an integration time step of 2.0 fs;
the neighbor list was updated every 10 steps. Electrostatic
interactions were described using the particle-mesh Ewald method
[38], with a cutoff of 0.9 nm for real-space interactions, and a
0.12-nm grid with fourth-order B-spline interpolation for recipro-
cal-space interactions.
Adiabatic Biased MD Simulations
The starting equilibrated unliganded conformation of the B2AR
within the lipid bilayer was subjected to ten independent Adiabatic
Biased MD (ABMD) simulations [39,40] to obtain transition
pathways of the receptor from an inactive to an active
conformation, built using the coordinates of the nanobody-
stabilized crystal structure (PDB code: 3P0G). Briefly, this method
biases the system towards a given value x0 of a predefined order
parameter x(R), where R represents the coordinates of the atoms
in the system. A harmonic bias acts only when the distance of x(R)
from the target x0 is bigger than its minimum value previously
reached during the simulation (i.e. if x(R(t))- x0 . mins,t x(R(s))-
x0), according to the following equation:
V(R(t))~k(x(R(t)){x0)
2 ð1Þ
The order parameter x measures the distance from the putative
activated conformation of the receptor, and is defined as the Ca
root mean square deviation (RMSD) from the active conformation
of the B2AR (all residues were included except the long flexible
IL3). In order to obtain activated final states, the simulation was
run with x0=0. After carrying out 10 independent ABMD runs
with an elastic constant of k=10 kcal/(mol?nm
2), the trajectories
were pooled and clustered using an average linkage agglomerative
algorithm and the same dissimilarity measure used to run ABMD.
Ligands Parameters
Bonded and van der Waals interactions for the ligands were
assigned manually choosing the appropriate OPLS-AA atom types
[30] for each atom in the molecule. Coulomb point charges were
obtained according to the RESP approach [41] from quantum
chemical calculations (i.e., geometry optimization using Gaussian
03 [42] and restricted Hartree-Fock calculations with the 6-31G*
basis set).
Ligand Docking
Ligands for which an experimental crystal structure in complex
with the B2AR is available, i.e. 2RH1 for carazolol [19], 3NY8 for
ICI-118,551 [21], and 3NYA for alprenolol [21], were positioned
in the binding pocket accordingly. The other ligands, i.e. the full
agonist epinephrine and the partial agonists dopamine and
catechol, were docked into the initial inactive model of B2AR,
using a standard Autodock 4.0 protocol [43,44]. Inferences from
agonist-bound crystal structures of B2AR [10,11] and B1AR [13]
were taken into account when selecting the most accurate initial
binding poses of these ligands for free-energy calculations.
Notably, simulations of initial conformations comprising slightly
different binding poses produced similar free-energy profiles (data
not shown).
Metadynamics
The free-energy profiles of liganded and unliganded systems
were estimated using metadynamics [45–47]. Briefly, this
technique enables an efficient reconstruction of the free-energy
as a function of a set of k predetermined order parameters, referred
to as collective variables si(R), 1#i#k. A history-dependent bias
potential is added to the force-field driving the system dynamics so
as to discourage the re-visiting of regions of the si phase space that
have already been explored. Specifically, the bias potential is
V(R,t)~
X
t0vt
wt0 P
k
i~1
exp {
½si(R(t)){si(R(t0)) 
2
s2
i
 !
ð2Þ
where t9 is a multiple of a deposition time t and the values of wt9
and si regulate the shape and size of the Gaussian bias
contributions. In the original metadynamics algorithm, wt9=wis
constant, and the free-energy profile can be estimated up to
an insignificant additive time-dependent constant as W(R) =
2 limtR‘ V(R,t).
Here, we used well-tempered metadynamics [24], a variant of
the original metadynamics algorithm that enables assessment of
simulation convergence while keeping the computational effort
focused on physically relevant regions of the conformational space.
In this variant of the method, the value of wt9 depends on the bias
accumulated up to t9 according to the equation:
wt0~wexp {
V(R,t0)
kBDT
  
ð3Þ
where DT is a constant with the dimension of a temperature, kB is
the Boltzmann constant, and w is a constant energy representing
the maximum height of the Gaussian biases. Since in the regions
where the bias is higher the exponential factor reduces the rate of
the bias update, the bias potential smoothly converges to a
constant value in time, and the underlying free-energy can be
derived by
W(R)~{ lim
t??
TzDT
DT
V(R,t) ð4Þ
where T is the temperature at which the simulation is performed.
To efficiently sample the conformational space along the
activation pathway, reference states from the clustered ABMD
runs were selected by cutting the agglomerative tree at 30 clusters,
and selecting from them n=10 clusters homogeneously covering
the pathway. The reference states Rj (1#j#n) were numbered
assigning j=1 to the cluster closer to the inactive state (Ca RMSD
from 2RH1 ,0.4 A ˚) and j=10 to the one closer to the active state
(Ca RMSD from 3P0G ,0.3 A ˚). Two path collective variables
describing the position along (s) and the distance from (z) the
pathway were defined [48] as follows:
s~
1
Z
X n
j~1
j{1
n{1
exp {cd(R,Rj)
  
ð5Þ
z~{
1
c
lnZ ð6Þ
where d(R,Rj) is the squared Ca RMSD (excluding IL3) with
respect to the reference structure Rj, and Z = g1#j#n exp(2 c
d(R,Rj)). The simulations were performed choosing c = 1/0.25
A ˚ -2, ss=0.1, and sz=1A ˚ 2, and well-tempered metadynamics
was used with a bias factor DT=10 T, an initial value of w=
0.4 kcal/mol, and a deposition interval t=8 ps. Metadynamics
simulations were run for 300 ns, time at which the reconstructed
Towards Ligand-Specific Conformations of GPCRs
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0.2 kcal/mol.
Free-Energy Calculations
Since the trajectory was generated adding the metadynamics
bias, the resulting conformations cannot be used to obtain
statistical information on order parameters other than the
collective variables. However, it is possible to unbias the
distribution of any given function of the system coordinates using
the algorithm described in [49]. This so-called reweighting
technique was used to estimate the free-energy surface of the
complexes as a function of three important descriptors of receptor
activation, namely the distance between R3.50 and E6.30 (the
‘‘ionic lock’’), the rotamer of residue W6.48 (the so-called ‘‘toggle
switch’’), and the outward displacement of the intracellular
segment of TM6.
Three order parameters were defined to monitor the behavior
of these changes upon activation. For the ionic lock, we defined
dIL=| | ÆR3.50æ 2 ÆR6.30æ||, where ÆR3.50æ and ÆR6.30æ represent
the center of mass of the g-nitrogens of R3.50 and the d-oxygens
of E6.30, respectively. For the toggle switch, we monitored the first
dihedral angle xTS of the side chain of W6.48. Finally, the
movement of TM6 was measured by aligning the receptor to the
inactive crystal structure (2RH1) and calculating the distance
dTM6 =| | M 2 ÆR6.35æ|| (angled brackets indicate the centroid
of all the atoms of the residues) between the midpoint of an
imaginary line connecting residues K6.35 and Y2.41 in the
inactive structure, M = K[ÆR2.41æ+Æ R6.35æ] (located roughly at
the center of the intracellular exposed surface of the receptor), and
residue K6.35. The outward movement is described by the
difference in dTM6 values between any given conformation and the
reference inactive crystal structure, i.e. by DdTM6=d TM6–dTM6
(2RH1).
Unbiased Simulations
Representative conformational states of the metastable energy
basins identified by metadynamics were selected and their
structural stability analyzed. Specifically, standard, unbiased,
NPT molecular dynamics simulations of these conformational
states were initiated by randomizing new initial starting velocities
with the Maxwell distributions at 300 K, and were run for ,50 ns
using the same simulation parameters described above.
Results
We calculated the free-energy profile of the B2AR in an explicit
POPC/10% cholesterol membrane bilayer along an activation
pathway connecting two recently determined inactive [19] and
active [10] crystallographic states of the receptor. Specifically, the
receptor was studied in its unliganded form as well as in complex
with the full agonist epinephrine, the weak partial agonist
dopamine, the very partial agonist catechol, the inverse agonist
ICI-118-551, the inverse agonist carazolol, or the neutral
antagonist alprenolol. All free-energy values at the active and
inactive states, and the barriers between them, are summarized in
Table 1.
Unliganded Receptor
An activation pathway from the inactive to the active B2AR
crystal structures (PDB codes 2RH1 and 3P0G, respectively) was
obtained by ABMD following the protocol described in the
Materials and Methods section. This pathway was used to define
the s and z collective variables (see the Materials and Methods
section for corresponding equations) that were employed for the
metadynamics simulations. Panel A of Figure 1 illustrates the free-
energy ?G of the unliganded receptor as a function of the position s
along the activation pathway following integration of the
dependence on z. Specifically, s=0.0 and s=1.0 indicate the
inactive and fully activated extreme conformations of the pathway,
respectively. This free-energy profile shows two minima, one at
s,0.2 that is close to the inactive state and the other at s,0.6 that
is shifted towards the active state. The two states are separated by
a barrier of ,2.5 kcal/mol, but they have a similar overall stability
(DG,kBT), and are therefore equally populated at equilibrium.
Inspection of the entire two-dimensional free-energy profile
DG(s,z) reported in the supplementary material (see panel A of
Figure S2) shows that these states correspond to conformations
along the activation pathway with values of z close to 0. Visual
inspection of a representative structure of the s,0.2 energy basin
confirms that the corresponding transmembrane bundle is very
close to the inactive B2AR crystal structure (Ca RMSD excluding
IL3 ,0.6 A ˚), as substantiated by the very small outward
movement of TM6 (DdTM6 , 0.4 A ˚) with respect to the inactive
crystal (see panel B of Figure S2). In contrast, a representative
structure of the second energy basin at s,0.6 (RMSD ,1.6 A ˚ and
,1.1 A ˚ from the inactive and active crystal structures, respective-
ly) displays a more pronounced outward movement of TM6
(DdTM6 ,2.5 A ˚ in Figure S2).
Figure 1B shows the free-energy of the unliganded B2AR as a
function of order parameters that monitor molecular switches
which have traditionally been reported as descriptors of GPCR
activation. Specifically, these molecular switches are: 1) the ionic
lock between TM3 and TM6, herein monitored using the distance
dIL between R3.50 and E6.30 and 2) the W6.48 rotamer toggle
switch, herein monitored using the first dihedral angle xTS of the
residue side chain. Whilst the latter has not been observed in
recent activated crystal structures of GPCRs, compelling spectro-
scopic data exist supporting a rotamer change of the W6.48 side
chain upon activation [50]. Two different energy basins can be
identified in the plot of Figure 1B: a more stable one, labeled a,i n
which both molecular switches are in their inactive conformation
(dIL,3A ˚ and xTS,163u), and a second basin, labeled c, where
both switches are in their activated conformation (dIL,12 A ˚ and
xTS,55u). The two basins are separated by a barrier of
,3.0 kcal/mol. A transition state at xTS,65u and dIL,5A ˚
Table 1. Relative free2energy values (in kcal/mol) of the
inactive, intermediate, and active states of the unliganded
and liganded B2AR, together with the height of the barriers
separating them.
Inactive
(s,0.2) TS1
Intermediate
(s,0.6) TS2
Active
(s,0.9)
Unliganded 0.0
* 3.0 0.0 22
Alprenolol 0.0
* 3.3 1.0 22
Carazolol 0.0
* 5.9 4.0 22
ICI-118,551 0.0
* 5.2 3.8 22
Epinephrine 1.0 4.1 1.8 6.0 0.0
*
Catechol 1.0 2.2 0.0
* 22
Dopamine 1.5 4.2 0.0
* 22
TS1 represents the transition state between the inactive and the intermediate
states, while TS2 represents the transition state between the intermediate state
and the active one. The most stable state for each system is indicated with a
star.
doi:10.1371/journal.pcbi.1002193.t001
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toggle switch prior disruption of the ionic lock.
Receptor Bound to a Neutral Antagonist
The neutral antagonist alprenolol, consisting of an ‘‘aromatic
head’’ (a 2-allyl-pheniloxyl moiety) and an ‘‘aliphatic tail’’ (oxy-
propanol-amine) (see chemical structure in Figure 2A), was docked
in accordance to the binding mode assumed by the ligand in the
crystal structure of the corresponding ligand-bound receptor [21].
The results of the simulations for the alprenolol-bound receptor
are illustrated in panels A-C of Figure 2. As shown in Figure 2A,
the overall shape of the free-energy profile of the alprenolol-bound
B2AR as a function of the position (s) along the activation pathway
is qualitatively similar to the profile obtained for the unliganded
receptor, and reported in Figure 1A. A similarity is also noted
between the two-dimensional energy surfaces of the alprenolol-
bound (Figure S3A) and the unliganded B2AR (Figure S2A). In
spite of these qualitative similarities, the inactive state at s,0.2 is
more stable (,1 kcal/mol) than the intermediate state at s,0.6 for
the alprenolol-bound receptor compared to the unliganded one.
Given the relatively higher stability of the alprenolol-bound
receptor conformation with no significant outward movement of
TM6 (DdTM6 ,0.4 A ˚ at s,0.2 in Figure S3B), these results
suggest an energy profile that is more suitable for a very weak
inverse agonist rather than a neutral antagonist. Notably, data are
available in the literature in support of an inverse agonist [51,52]
(or even a partial agonist [53]) role for alprenolol.
Figure 2B shows a representative conformation of the lowest
energy basin identified for the alprenolol-bound receptor. In this
conformation, and similar to the corresponding crystal structure
[21], the alprenolol charged moiety in its aliphatic tail forms
interactions with polar residues D3.32 and N7.39, while the ligand
aromatic head interacts with residues V3.33, V3.36, F6.51, N6.55,
Y5.38, and S5.42, which define a cleft formed by TM3, TM5 and
TM6. Figure 2C shows that the energetically most stable
alprenolol-bound inactive state is characterized by inactive
molecular switches (xTS,160u and dIL,5A ˚). This state, labeled
a in Figure 2C, is separated by an energy barrier of ,3 kcal/mol
from the second most stable energetic minimum at xTS,50u and
dIL,12 A ˚ (c in Figure 2C), with a transition state (b in Figure 2C)
at xTS,85u and dIL,5A ˚. Thus, the presence of alprenolol in the
binding pocket does not appear to disrupt the free-energy profile
Figure 1. Free-energy of the unliganded receptor. (A) Free-energy as a function of the position (s) along the activation pathway. Note that the
curve has been shifted so that the lowest energy minima (indicated by stars) correspond to a reference free-energy value. (B) Free-energy as a
function of ionic lock distance (dIL) and the toggle switch dihedral (xTS) molecular switches for the unliganded receptor; contour lines are reported
every kBT.
doi:10.1371/journal.pcbi.1002193.g001
Figure 2. Simulation results for B2AR bound to the neutral antagonist alprenolol. (A) Free-energy profile as a function of the position (s)
along the activation pathway. Note that the curve has been shifted so that the minimum (indicated by a star) corresponds to a reference free-energy
value. (B) Binding mode of alprenolol. Relevant residues interacting with the ligand (any atom within a 3 A ˚ distance cutoff) are indicated in stick
representations. Helices TM5, TM6 and TM7 are shown in orange, blue and light blue respectively. Helix TM3 is shown in purple transparent
representation whereas TM4 has been removed for clarity. (C) Free-energy as a function of ionic lock distance (dIL) and the toggle switch dihedral
(xTS) molecular switches.
doi:10.1371/journal.pcbi.1002193.g002
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rotamer toggle switch of the W6.48 residue prior breaking of the
ionic lock. The stability of alprenolol in a representative state of
the ligand-receptor complex extracted from the most stable energy
basin at s,0.2 was confirmed by carrying out ,50 ns unbiased
MD simulations. The evolution of the ligand and the protein
RMSD during these simulations is reported in Figure S4.
Receptor Bound to Inverse Agonists
We assessed the effect of two different B2AR inverse agonists,
namely ICI-118,551 and carazolol, on the free-energy landscape
of the receptor during transition from inactive to activated
experimental states. Carazolol and ICI-118,551 share important
structural features with alprenolol, e.g., they both have an
‘‘aliphatic tail’’ (oxy-propanol-amine for carazolol and oxy-
butanol-amine for ICI-118,551) and an ‘‘aromatic head’’. The
results of the simulations for the carazolol-bound and the ICI-
118,551-bound receptor are illustrated in panels A-C and D-F of
Figure 3, respectively.
In the presence of either carazolol or ICI-118,551, the B2AR
free-energy profiles (Figure 3A and 3D, respectively) show a single
lowest-energy basin at s,0.18 close to the inactive state of the
receptor. These much more stable energy basins are also present
in the two-dimensional energy surfaces of the carazolol-bound
(Figure S5A) and the ICI-118,551-bound (Figure S5C) B2AR, and
comprise inactive conformations as further illustrated by the lower
energy values for states characterized by the absence of outward
movement of TM6 (DdTM6 , 0.4 A ˚ in Figures S5B and S5D).
Representative conformations extracted from the lowest energy
basins of either the carazolol-bound (Figure 3B) or the ICI-
118,551-bound (Figure 3E) receptors show that the energy-
optimized binding poses of these ligands are very similar to their
positions in the corresponding crystal structures [19,21]. Similar to
the binding mode of alprenolol, the charged moieties contained in
the aliphatic tails of these ligands interact with polar residues
D3.32, and N7.39, while their aromatic heads are oriented toward
TM3, TM5, and TM6, thus directly interacting with residues in
these helices (see Figures 3B and 3E). To assess the stability of the
ligands in these representative conformations, we performed
standard, unbiased MD simulations. As shown in Figures S6A-
D, which report the time evolutions of the RMSD of the protein,
as well as those of the heavy atoms of carazolol and ICI-118,551,
after superposition of the receptor Ca atoms, the receptor
conformations are stable and the binding modes of the ligands
are conserved over a simulation time of ,50 ns.
The intermediate state at s,0.6 that was significantly populated
in the unliganded and neutral antagonist-bound receptor is much
less stable at DG,4.0 kcal/mol in the case of the carazolol-bound
or ICI-118,551-bound receptors (see Figures 3A and 3D,
respectively). However, these are still metastable states, as judged
by the presence of shallow minima at s,0.6 in both the free-
energy profiles, and are separated from the inactive states by
multiple barriers. In terms of modulation of the toggle switch and
the ionic lock, the free-energy as a function of xTS and dIL
Figure 3. Simulation results for B2AR bound to the inverse agonists carazolol and ICI-118,551. (A and D) Free-energy profiles as a
function of the position (s) along the activation pathway for carazolol and ICI-118,551, respectively. Note that the curves have been shifted so that the
minima (indicated by stars) correspond to reference free-energy values. (B and E) Binding modes of carazolol and ICI-118,551, respectively. Relevant
residues interacting with the ligands (any atom within a 3 A ˚ distance cutoff) are indicated in stick representations. Helices TM5, TM6 and TM7 are
shown in orange, blue and light blue respectively. Helix TM3 is shown in purple transparent representation whereas TM4 has been removed for
clarity. (C and F) Free-energies as a function of ionic lock distance (dIL) and the toggle switch dihedral (xTS) molecular switches for the carazolol- and
ICI-118,551-bound B2AR, respectively.
doi:10.1371/journal.pcbi.1002193.g003
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bound complexes, respectively) features only one minimum in the
inactive region of these molecular switches (xTS,160u and
dIL,3A ˚).
Receptor Bound to Agonists
To study the effects of full agonists on the free-energy landscape
of B2AR, we docked epinephrine into the receptor, and performed
metadynamics calculations. Figure 4A shows the free-energy
profile of the epinephrine-bound B2AR with the lowest energy
state (s,0.9) likely to correspond to an activated conformation.
The same observation is possible by inspection of the two-
dimensional free-energy surface (Figure S7A) as well as the TM6
outward movement (DdTM6 ,5.9 A ˚ in Figure S7B) as a function
of the position s along the activation pathway. However, a second
low-energy metastable state is present in these free-energy profiles,
close to the inactive state (s,0.2), and with a free-energy difference
of only ,1 kcal/mol with respect to the most stable activated
state.
As illustrated in Figure 4B, our proposed binding mode of
epinephrine within a fully activated B2AR (energy basin at s,0.9)
is consistent with the binding poses displayed by full agonists in the
B2AR [10] and B1AR [13] crystallographic structures. Specifi-
cally, the ligand amino group forms hydrogen bonds with D3.32
and N7.39 of B2AR, the ligand b-hydroxyl group interacts with
D3.32, and the ligand catecholamine hydroxyl groups interact
Figure 4. Simulation results for B2AR bound to the full agonist epinephrine, the very weak partial agonist catechol, and the weak
partial agonist dopamine. (A, D, and G) Free-energy profiles as a function of the position (s) along the activation pathway for epinephrine,
catechol, and dopamine, respectively. Note that the curves have been shifted so that the minima (indicated by stars) correspond to reference free-
energy values. (B, E, and H) Binding modes of epinephrine, catechol, and dopamine, respectively. Relevant residues interacting with the ligands (any
atom within a 3 A ˚ distance cutoff) are indicated in stick representations. Helices TM5, TM6 and TM7 are shown in orange, blue and light blue
respectively. Helix TM3 is shown in purple transparent representation whereas TM4 has been removed for clarity. (C, F, and I) Free-energies as a
function of ionic lock distance (dIL) and the toggle switch dihedral (xTS) molecular switches for the epinephrine-, catechol-, and dopamine-bound
B2AR, respectively.
doi:10.1371/journal.pcbi.1002193.g004
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S5.46. In this state, the B2AR helix bundle is structurally very
similar to the corresponding nanobody-activated crystal structure
of the receptor (C? RMSD from 3P0G is ,1.6 A ˚). The stability of
the epinephrine binding pose and the specific receptor conforma-
tion were verified by carrying out ,50 ns standard MD
simulations (see corresponding time evolutions of RMSD in
Figure S8). On the other hand, representative structures of the
energy basin at s,0.2 (data not shown) corresponded to
conformations of the helix bundle very similar to the inactive
crystal structure of B2AR (Ca RMSD from 2RH1 is ,1.0 A ˚).
Two energy basins (labeled a and c) were identified from the
free-energy as a function of the order parameters describing the
ionic lock and rotamer toggle switches (Figure 4C). Specifically,
the basin comprising conformations in which both the ionic lock
and rotamer toggle switches are in the ‘active’ (dIL,16 A ˚ and
xTS,50u) positions appear to be more stable than the basin with
receptor conformations with ‘inactive’ (dIL,3A ˚ and xTS,160u)
molecular switches. Also in this case, the minimum free-energy
path between these two energy basins suggests activation of the
toggle switch prior breaking of the ionic lock interaction along the
path to full receptor activation.
Receptor Bound to Partial Agonists
The weak and very weak partial agonists, dopamine and
catechol, were also simulated in the context of the B2AR
activation pathway. Figures 4D and 4G illustrate the free-energy
profiles of the catechol-bound and dopamine-bound receptors,
respectively. In both cases the receptor is most stabilized in an
intermediate state (s,0.6) along the pathway to activation.
Inspection of the free-energy as a function of the position (s) along
and the distance (z) from the activation pathway (see Figures S9A
and S9C for the catechol-bound and dopamine-bound receptors,
respectively) confirms that these two ligands stabilize a state
different from the inactive or fully activated ones as judged by the
lowest energy values at z,2 in Figure S9A for catechol, and at
s,0.6, z,0.0 in Figure S9C for dopamine. This difference is also
evident from the free-energy surfaces as a function of the TM6
outward movement and the position along the activation pathway
(see Figures S9B and S9D, respectively), as well as from the
structural superpositions shown in Figure 5. Specifically, Figure 5
illustrates the structural differences between the TM regions of the
predicted inverse agonist- and partial agonist-specific conforma-
tions (Figure 5A), the inverse agonist- and full agonist-specific
conformations (Figure 5B), and the partial agonist- and full
agonist-specific conformations (Figure 5C).
Figures 4E and 4H show the binding modes of catechol and
dopamine, respectively. These binding poses were proven to be
stable during ,50 ns of unconstrained MD simulations (see
Figures S10A and S10B for the time evolution of the RMSD of
catechol and dopamine, respectively, and Figures S10C and S10D
for the time evolution of the RMSD of the corresponding protein
Ca atoms). In agreement with inferences from recent B1AR
structures co-crystallized with either full or partial agonists, these
two B2AR partial agonists formed stable hydrogen bonds (through
the catechol moiety) with the side chain of S5.42, but do not with
S5.46. In terms of the ligand-induced modulation of the molecular
switches, the catechol-bound B2AR state with a broken ionic lock
(located at xTS,50u and dIL,16 A ˚ in Figure 4F) is relatively less
stable than the corresponding larger basin identified in the
presence of dopamine (see Figure 4I), consistent with spectroscopy
data suggesting that catechol is unable to disrupt the ionic lock [9].
Discussion
Understanding the molecular mechanisms underlying GPCR
functional selectivity is extremely important in modern drug
discovery, since it provides a unique opportunity for the
identification or rational design of ‘biased’ ligands as novel more
effective therapeutics. Epitomizing an emerging paradigm in
current drug discovery [54], native states of GPCRs can be
assumed in a dynamic equilibrium between different conforma-
tional sub-states [11,18,55], which correspond to the valleys of an
energy landscape, the barriers of which reflect the timescales of the
conformational exchange. The relative populations of these sub-
states follow statistical thermodynamics distributions and are
shifted towards specific conformations as a consequence of ligand
binding and/or other allosteric events such as those induced by
protein-protein interactions. Thus, ligands with varied efficacies
are believed to modulate the free-energy landscape of a GPCR,
Figure 5. Structural comparisons between ligand-specific B2AR conformations. Specifically, these comparisons (viewed from the
intracellular side) are between: (A) an inverse agonist (carazolol)-bound inactive state at s,0.2 (blue color) and a partial agonist (dopamine)-stabilized
intermediate conformation at s,0.6 (orange color); (B) an inverse agonist (carazolol)-bound inactive state at s,0.2 (blue color) and a full agonist
(epinephrine)-stabilized active conformation at s,0.9 (pink color); and (C) a partial agonist (dopamine)-bound intermediate conformation at s,0.6
(orange color) and a full agonist (epinephrine)-stabilized active conformation at s,0.9 (pink color). The position of the side chains of the residues
involved in the ionic locks are indicated with sticks. For clarity, IL3 has been removed.
doi:10.1371/journal.pcbi.1002193.g005
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conformations of the receptor, depending on their pharmacolog-
ical action.
A reliable characterization of the specific conformations that
inverse agonists, agonists (both full and partial), or antagonists can
stabilize in a given GPCR is highly desirable for the structure-
based discovery of novel ligands eliciting selected functional
responses. This is difficult to achieve by X-ray crystallography for
the majority of GPCRs due to their intrinsic structural instability,
and the realization that the majority of pharmacologically active
ligands are not ideal compounds for receptor stabilization that is
suitable for crystallization.
The enhanced sampling approach we describe here provides
atomic-resolution information of receptor conformations along
pre-determined activation pathways that are differentially stabi-
lized by ligands with different efficacies. Our approach also
provides a quantitative description of the thermodynamics of the
B2AR basal activity, with the unliganded receptor being able to
sample both an inactive state and an intermediate state that is
shifted towards the activated conformation. This latter state is
structurally different from the fully active state of B2AR captured
by the nanobody-stabilized crystal structure. Although it exhibits a
broken ionic lock and a cytoplasmic opening that is able to
accommodate the camelid antibody, a few clashes are produced by
the much smaller outward movement of TM6 (,2.5 A ˚ compared
to the ,5.9 A ˚ that can be achieved by a full agonist). Given the
small free-energy difference between the two lowest energy
minima identified for the unliganded B2AR, these two states are
almost equally populated at equilibrium, in agreement with the
high basal activity of the B2AR. Moreover, the relatively low
energy barrier between the two states is consistent with the flexible
nature of the unliganded B2AR, and the consequent difficulty in
obtaining crystals of the native receptor.
We observed a more or less pronounced perturbation of the
free-energy profile of the unliganded B2AR depending on the
ligand considered for binding. Although alprenolol has often been
described as a neutral antagonist of B2AR, its presence in the
B2AR binding pocket slightly modifies the free-energy profile of
the receptor, making the inactive state more stable in spite of the
small difference in free-energy (,kBT). This result is not
completely surprising in light of the evidence existing in the
literature for a role of alprenolol as an inverse agonist or even a
weak agonist, depending on the assay used [56,57].
Our results show that the selection of a single conformational
state is particularly effective in the case of inverse agonists. The
docking of either carazolol or ICI-118,551 in the receptor
dramatically changes the free-energy landscape of B2AR and
reduces it to a funneled profile with a single major basin
corresponding to the inactive conformation. This result is consistent
with the greater availability of crystals of B2AR in an inactive
conformation stabilized by potent inverse agonists in the binding
pocket, and with the observation that the structural features of the
inactive states of the various receptors obtained so far are similar.
The situation is different when we study the free-energy
landscape in the presence of agonists. The computational
experiment with epinephrine shows that a full agonist is capable
of stabilizing a state of B2AR presenting structural features that
have been found in the nanobody-stabilized agonist-bound crystal
structure of B2AR. However, in addition to this active state, we
obtain a relatively stable agonist-bound inactive state that is
structurally similar to the inverse agonist-bound crystal structure
of B2AR. This is not surprising, given the absence of TM6 outward
movements noted in both the B2AR crystal structure with a
covalently-bound agonist [11], and the agonist-bound B1AR crystal
structures [13]. Moreover, the relatively small difference in free-
energy between the fully active and the inactive agonist-bound
conformations is probably due to the lack of the G-protein in the
simulation setup, in line with the observation deriving from the two
recent agonist-bound B2AR crystal structures [10,11] that a ligand
alone is not sufficient to stabilize a fully active crystallographic state
of the receptor, buta G-proteinmimickingnanobody is necessary to
trap this conformation. Different from the crystallographic
information, but in line with experimental evidence from
fluorescence spectroscopy [9], we find that metastable states
corresponding to fully (and partial) activated conformations of the
receptor favor the rotamer change of the W6.48 side chain.
The partial agonism elicited by dopamine and catechol shifts
the conformational equilibrium towards states that are different
from that stabilized by the full agonist, and captured in the
nanobody-stabilized crystal structure. In particular, the two
ligands affect the free-energy landscape in different ways. While
the intermediate dopamine-bound state always features a broken
ionic lock, the receptor samples conformations that have different
ionic lock states when catechol is in the binding pocket. Notably,
experimental evidence from fluorescence spectroscopy [9] also
suggested that the very weak partial agonist catechol is not able to
completely disrupt the interaction between the charged residues at
the cytoplasmic end of TM3 and TM6. Structurally, the two
conformations stabilized by catechol and dopamine are different in
the degree of separation between the extracellular ends of TM5
and TM6 and between the intercellular ends of TM3 and TM6.
Consistent with the hypothesis that global structural features of the
receptor, such as the tilt of the extracellular half of TM5, can
optimize the binding to agonists [58], we see a larger TM5 tilt in
the presence of dopamine (as well as for epinephrine) and a smaller
one in the presence of catechol. Owing to the greater ability of
catechol to stabilize a state with a formed ionic lock, the
intracellular ends of TM3 and TM6 also appear slightly closer
(by ,1A ˚) together.
In summary, we have designed a strategy using a combination
of different adaptive biasing techniques that enables characteriza-
tion of reliable ligand-specific conformations as demonstrated here
in the case of B2AR. The strategy is completely general and may
be of practical use for the structure-based design of ‘biased’ ligands
that selectively activate signaling pathways, and may therefore
exhibit improved therapeutic properties.
Supporting Information
Figure S1 Ribbon representation of the B2AR illustrat-
ing the secondary structure motifs and the residues used
to monitor activation. Residues involved in the ‘‘ionic lock’’
(R3.50 and E6.30) and the ‘‘toggle switch’’ (W6.48) are indicated
with sticks. The midpoint between residue Y2.41 and E6.30 is
indicated with a purple dot and the approximate location of the
binding pocket with a red sphere. Transmembrane helices are
colored (TM1 in red, TM2 in orange, TM3 in purple, TM4 in
brown, TM5 in yellow, TM6 in transparent blue, and TM7 in
light blue).
(TIF)
Figure S2 Additional analyses of the simulations of the
unliganded B2AR. (A) Free-energy of the unliganded B2AR as a
function of the position along (s) and the distance from (z) the
activation pathway. The surface has been shifted so that the lowest
energy minima correspond to reference free-energy values;
contours are spaced by 2 kcal/mol. (B) Free-energy projection as
a function of the path variable s and the displacement of TM6.
The latter is defined by the distance between the midpoint of an
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the center of the intracellular exposed surface of the receptor) and
residue K6.35.
(TIF)
Figure S3 Additional analyses of the simulations of the
B2AR bound to the neutral antagonist alprenolol. (A)
Free-energy of the as a function of the position along (s) and the
distance from (z) the activation pathway. The surface has been
shifted so that the lowest energy minima correspond to reference
free-energy values; contours are spaced by 2 kcal/mol. (B) Free-
energy projection as a function of the path variable s and the
displacement of TM6. The latter is defined by the distance
between the midpoint of an imaginary line connecting residues
K6.35 and Y2.41 (roughly at the center of the intracellular
exposed surface of the receptor) and residue K6.35.
(TIF)
Figure S4 Time evolution of the RMSD of alprenolol
and B2AR. RMSD vs. time of (A) the alprenolol heavy atoms
after alignment of the B2AR Ca atoms and (B) the B2AR Ca
atoms with respect to the initial conformation. The initial structure
was extracted from the s,0.2 and z,0.0 A ˚ basin in figure S3.
(TIF)
Figure S5 Additional analyses of the simulations of the
B2AR bound to the inverse antagonists carazolol and
ICI-118,551. (A and C) Free-energy of carazolol- and ICI-
118,551-bound B2AR as a function of the position along (s) and
the distance from (z) the activation pathway. The surface has been
shifted so that the lowest energy minima correspond to reference
free-energy values; contours are spaced by 2 kcal/mol. (B and D)
Free-energy projection as a function of the path variable s and the
displacement of TM6 for the inverse agonists carazolol- and ICI-
118,551-bound B2AR, respectively. The latter is defined by the
distance between the midpoint of an imaginary line connecting
residues K6.35 and Y2.41 (roughly at the center of the
intracellular exposed surface of the receptor) and residue K6.35.
(TIF)
Figure S6 Time evolution of the RMSD of carazolol, ICI-
118,551, and B2AR. RMSD vs. time of the (A) carazolol and (B)
ICI-118,551 heavy atoms after alignment of the B2AR Ca atoms,
and the B2AR Ca atoms in the simulations with (C) carazolol or (D)
ICI-118,551withrespecttotheinitialstructure.Theinitialstructure
was extracted from the s,0.2 and z,0.0 A ˚ basins in Figure S5.
(TIF)
Figure S7 Additional analyses of the simulations of the
B2AR bound to the full antagonist epinephrine. (A) Free-
energy of the full agonist epinephrine-bound B2AR as a function
of the position along (s) and the distance from (z) the activation
pathway. The surface has been shifted so that the lowest energy
minima correspond to reference free-energy values; contours are
spaced by 2 kcal/mol. (B) Free-energy projection as a function of
the path variable s and the displacement of TM6. The latter is
defined by the distance between the midpoint of an imaginary line
connecting residues K6.35 and Y2.41 (roughly at the center of the
intracellular exposed surface of the receptor) and residue K6.35.
(TIF)
Figure S8 Time evolution of the RMSD of epinephrine
and B2AR. RMSD vs. time of (A) the epinephrine heavy atoms
after alignment of the B2AR Ca atoms, and (B) the B2AR Ca
atoms with respect to the initial structure. The initial structure was
extracted from the s,0.9 and z,0.5 A ˚ basins in Figure S7.
(TIF)
Figure S9 Additional analyses of the simulations of the
B2AR bound to the partial agonists catechol and dopa-
mine. (A and C) Free-energy of the partial agonists catechol- and
dopamine-bound B2AR as a function of the position along (s)a n d
the distance from (z) the activation pathway. The surface has been
shifted so that the lowest energy minima correspond to reference
free-energy values; contours are spaced by 2 kcal/mol. (B and D)
Free-energy projection as a function of the path variable s and the
displacement of TM6 for the partial agonists catechol- and
dopamine-bound B2AR, respectively. The latter is defined by the
distance between the midpoint of an imaginary line connecting
residues K6.35 and Y2.41 (roughly at the center of the intracellular
exposed surface of the receptor) and residue K6.35.
(TIF)
Figure S10 Time evolution of the RMSD of catechol,
dopamine, and B2AR. RMSD vs. time of the (A) catechol and
(B) dopamine heavy atoms after alignment of the B2AR Ca atoms,
and of the B2AR Ca atoms in the simulations with (C) catechol or
(D) dopamine with respect to the initial structure. The initial
structure was extracted from the s,0.6 basins in Figure S9.
(TIF)
Table S1 List of the production runs performed in this
study. Number and length of independent simulations carried out
for each system.
(DOC)
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